.Attribute Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of clients along with HER2+ state-of-the-art breast cancer and energetic or even steady brain metastases revealed regular intracranial task and also systemic efficiency of T-DXd.